Wei-guo Su
CIK: 0002113925
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)2 (100.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
About Su Wei-guo
Su Wei-guo (SEC CIK 0002113925) files insider reports with the SEC as Director of ImageneBio, Inc. (IMA) and CEO and CSO of HUTCHMED (China) Ltd (HCM).
Signal8 holds 3 ownership filings by Su Wei-guo (2 Form 3, 1 Form 4), filed between Mar 16, 2026 and May 21, 2026. Those filings report 2 transactions, the latest on May 20, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Su Wei-guo's filings is in SAN DIEGO, CA.
Recent filings by Su Wei-guo
- May 20, 2026: Other transactions of HCM derivative securities (2 lines, Form 4, code J).
Other insiders filing for ImageneBio, Inc. (IMA)
- Yarema Kristin, Chief Executive Officer
- Grant-Huerta Yanina, Chief Financial Officer
- Lally Robert B, Principal Accounting Officer
- Wang Jonathan Jian, Director
- Stampacchia Otello, Director
- SLATTERY JOSEPH P, Director